eXp Realty Launches in Peru, Creating Unmatched Opportunities for Agents to Build Their Future 21-03-2025, 20:00

FactSet Schedules Second Quarter 2023 Earnings Call 23-02-2023, 19:02

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26